

## Supplementary material

### Rapid generation of recombinant *Pseudomonas putida* secondary metabolite producers using yTREX

Andreas Domröse<sup>1</sup>, Robin Weihmann<sup>1</sup>, Stephan Thies<sup>1</sup>, Karl-Erich Jaeger<sup>1,2</sup>, Thomas Drepper<sup>1</sup>, Anita Loeschcke<sup>1,\*</sup>

1, Institute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich, Jülich, Germany, and Bioeconomy Science Center (BioSC).

2, Institute of Bio- and Geosciences (IBG-1), Forschungszentrum Jülich, Jülich, Germany

\* corresponding author: Anita Loeschcke, a.loeschcke@fz-juelich.de

| content   | page |
|---|------|
| Tab. S1 Oligonucleotides used in this study                                   | 2    |
| Tab. S2 PCR fragments generated in this study                                 | 3    |
| Tab. S3 Plasmids used in this study   | 3    |
| Fig. S1 Plasmid maps  | 4    |
| Fig. S2 yTREX application scheme  | 5    |
| Fig. S3 prodigiosin gene cluster and pathway from <i>S. marcescens</i>        | 6    |
| Fig. S4 violacein gene cluster and pathway from <i>C. violaceum</i>           | 7    |
| Fig. S5 phenazine gene cluster and pathway from <i>P. aeruginosa</i>          | 8    |
| Tab. S4 Timeline of <i>P. putida</i> production strain generation using yTREX | 9    |

**Tab. S1: Oligonucleotides used in this study**


| No.   | Name            | Sequence 5'-3'   | Size [bp] |
|-------|-----------------|--|-----------|
| AD9   | AD9AphIIfwd     | GGAGTGGTGAATCCGTTAGCGAGGTGCCGCCGGCTTCAT<br>CGATCGCCCCGGATGAATGTCAGCTAC | 66        |
| AD10  | AD10AphIIrev    | AATCAATCTAAAGTATATGAGTAAACTGGTCTGACAGGA<br>GCTCGCTCAGAAGAACTCGTCAAG    | 66        |
| AD39  | AD39seqAphIIfwd | TCTGACGCTCAGTGGAAC   | 18        |
| AD40  | AD40seqAphIIrev | GCGCATTCACAGTTCTCC   | 18        |
| AD41  | AD41seqTREXfwd  | GATGAACAGGCAGACATC   | 18        |
| AD42  | AD42seqTREXrev  | GGCGAATCATGGACATAC   | 18        |
| AD65  | AD65GAvioALTREX | AGAAATATTAGCTAATTAACTCTCAACCCGGATGAAGCA<br>TTCTTCG                     | 50        |
| AD66  | AD66GAvioERTREX | GAAACAGCTATGACCATGATTACGCCAACGATCCAGGCCCT<br>AGCGCTTG                  | 49        |
| AD89  | AD89phzA        | AGAAATATTAGCTAATTAACTCTCAACCCGGCATACCTG<br>GAGAGCCCTCTCG               | 50        |
| AD90  | AD90HR-L-F      | GGCCGTTGAATCGGGATATG   | 20        |
| AD93  | AD93HR-R-R      | TAGCAGCACGCCATAGTGAC   | 20        |
| AD123 | AD123phzG       | GTAATCATGGTCATAGCTTTCTGTGTACGGTTGCA<br>GGTAGCGGTGCTTC                  | 55        |
| AD124 | AD124LacZstart  | CACACAGGAAACAGCTATGACCATGATTACGGATTCACTGG<br>CCGTCGTTTAC               | 53        |
| AD125 | AD125LacZend    | GAAACAGCTATGACCATGATTACGCCAACGCTAGCGCTTATT<br>TTTGACACCAGACC           | 55        |
| AD128 | AD128vioCr      | GCGGTTCCCGGTTTCCATGCGGCCCTCAGTTGACCCTC<br>CCTATCTTG                    | 50        |
| AD129 | AD129vioEf      | GGAGGCCGCATGGAAAACCGGGAAC  | 26        |
| AD130 | AD130vioBr      | GCGGTTCCCGGTTTCCATGCGGCCCTCAGGCCTCTA<br>GAAAGCTTCCAC                   | 54        |

**Tab. S2: PCR fragments generated in this study**


| Oligonucleotide pair | Template                      | Size [bp] | Genes              |
|----------------------|-------------------------------|-----------|--------------------|
| AD9/AD10             | pK18                          | 1155      | <i>aphII</i> (KmR) |
| AD65/AD66            | pAra-vio                      | 7398      | <i>vioABCDE</i>    |
| AD65/AD128           | pAra-vio                      | 5681      | <i>vioABC</i>      |
| AD65/AD130           | pAra-vio                      | 4390      | <i>vioAB</i>       |
| AD129/AD66           | pAra-vio                      | 624       | <i>vioE</i>        |
| AD89/AD123           | pUC18-pyo                     | 6363      | <i>phzABCDEFG</i>  |
| AD124/AD125          | pRcExplI2-YF1-FixJ-PFixK2lacZ | 3127      | <i>lacZ</i>        |

**Tab. S3: Plasmids used in this study**


| Plasmid                       | Relevant characteristics                                    | Reference             |
|-------------------------------|---|-----------------------|
| pAra-vio                      | KmR, <i>C. violaceum</i> ATCC12472 <i>vioABCDE</i>          | [1]                   |
| pK18                          | KmR   | [2]                   |
| pPIG                          | AmpR, <i>S. marcescens</i> W838<br><i>pigABCDEFGHIJKLMN</i> | [3]                   |
| pRcExplI2-YF1-FixJ-PFixK2lacZ | KmR, CmR, <i>lacZ</i>                                       | Loeschke, unpublished |
| pUC18-pyo                     | AmpR, <i>P. aeruginosa</i> PA01 <i>phzABCDEFG</i>           | Thies, unpublished    |
| YCp50-poly                    | URA3, CEN4/ARS1, AmpR, pMB1 ori                             | ATCC® 87555™<br>[4]   |
| YCp50-poly-KmR                | URA3, CEN4/ARS1, KmR, pMB1 ori                              | this study            |
| yTREX                         | YCp50-poly-KmR + L- & R-yTREX                               | this study            |
| yTREX-phzA-GlacZ              | <i>P. aeruginosa</i> PA01 <i>phzABCDEFG</i> , <i>lacZ</i>   | this study            |
| yTREX-pig                     | <i>S. marcescens</i> W838 <i>pigABCDEFGHIJKLMN</i>          | this study            |
| yTREX-vio                     | <i>C. violaceum</i> ATCC 12472 <i>vioABCDE</i>              | this study            |
| yTREX-vioABCE                 | <i>C. violaceum</i> ATCC 12472 <i>vioABCE</i>               | this study            |
| yTREX-vioABE                  | <i>C. violaceum</i> ATCC 12472 <i>vioABE</i>                | this study            |




**Fig. S1: All plasmids used in this study, including yTREX constructs, shown as plasmid maps.** Relevant features: AmpR, ampicillin resistance gene; KmR, kanamycin resistance gene; ori, bacterial origin of replication; URA3, pyrimidine ribonucleotide biosynthetic gene; CEN4/ARS1, *S. cerevisiae* origin of replication; L-yTREX & R-yTREX, yTREX cassettes; TcR, tetracycline resistance gene; lacZ, β-galactosidase encoding gene; phz, phenazine biosynthetic genes; pig, prodigiosin biosynthetic genes; vio, violacein biosynthetic genes.




**Fig. S2: yTREX application scheme.** The yTREX application consists of four steps, i.e. labelling, transfer, integration and expression. **(A)** yTREX labeling: Cloning of a gene cluster of interest in the CIS between the two yTREX cassettes in the yTREX vector. The respective gene cluster may be present on a vector such as a plasmid or cosmid (as depicted here) or may be obtained by PCR from chromosomal DNA. As opposed to the initial TREX system [3], this step can be accomplished via highly efficient yeast recombinational cloning. **(B)** Conjugational transfer of yTREX-labeled genes into a desired bacterial expression host. **(C)** Transposon Tn5-mediated randomized integration of the yTREX-transposon into the bacterial chromosome. An antibiotic resistance marker for tetracycline enables selection of clones with integrated transposon. **(D)** Expression of all clustered genes can either be implemented by T7 RNA polymerase in a bidirectional manner, using T7 promoters in the yTREX cassettes, as previously shown with the initial TREX system [3] (**D.1**). Alternatively, genes may be expressed by native chromosomal host promoters. Here, random insertion of the yTREX-transposon next to one strong promoter is sufficient for the expression of unidirectional gene clusters, as shown before with the initial TREX system [5] and further established in the present study. Note that for the expression of complex gene clusters with genes encoded in both directions, more unlikely insertion between two convergently oriented promoters is necessary (**D.2**). CIS, cluster integration site; OE, outside ends of transposon Tn5; oriT, origin of transfer; *tnp*, transposase gene;  $P_{T7}$ , T7 bacteriophage promoter;  $P_{host}$ , native chromosomal promoter of the expression host.



**Fig. S3: Prodigiosin biosynthetic gene cluster and pathway from *Serratia marcescens* W838.** Biosynthetic genes (**A**) and biosynthetic pathway (**B**) as elucidated previously [6,7]. AdoMet, S-adenosylmethionine; FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide; HBC, 4-hydroxy-2,2'-bipyrrole-5-carbaldehyde; HBM, 4-hydroxy-2,2'-bipyrrole-5-methanol; MAP, 2-methyl-3-n-amyl-pyrrole; MBC, 4-methoxy-2,2'-bipyrrole-5-carbaldehyde; NAD(P), nicotinamide adenine dinucleotide (phosphate); PLP, pyridoxal phosphate; TPP, thiamine pyrophosphate; ATP, adenosine triphosphate.



**Fig. S4: Violacein biosynthetic gene cluster and pathway from *Chromobacterium violaceum* ATCC 12472.**  
Biosynthetic genes (**A**) and biosynthetic pathway (**B**) as elucidated previously [8–10]. IPA, indole-3-pyruvic acid; NADP, nicotinamide adenine dinucleotide phosphate.



**Fig. S5: Phenazine biosynthetic gene cluster and pathway from *Pseudomonas aeruginosa* PAO1.** Biosynthetic genes (**A**) and biosynthetic pathway (**B**) as elucidated previously [11,12]. In *P. aeruginosa*, phenazine biosynthesis is encoded in two similar gene clusters, and an additional locus harboring *phzH*. Genes used in this study were *phzA1-G1*. E4P, erythrose-4-phosphate; PEP, phosphoenolpyruvate; DHAP, 3-deoxy-D-arabinoheptulosonic acid 7-phosphate; ADIC, 2-amino-2-deoxyisochorismic acid; DHHA, *trans*-2,3-dihydro-3-hydroxyanthranilic acid; AOCHC, 6-amino-5-oxocyclohex-2-ene-1-carboxylic acid; HHPDC, hexahydrophenazine 1,6-dicarboxylic acid; THPCA, tetrahydrophenazine-1-carboxylic acid; DHPCA, 5,10-dihydro PCA; PCA, phenazine-1-carboxylic acid; PCN, phenazine-1-carboxamide; 5MPCA, 5-methylphenazine-1-carboxylic acid; 1-HP, 1-hydroxyphenazine; PYO, pyocyanin; L-Gln, L-glutamine; L-Glu, L-glutamic acid; NAD, nicotinamide adenine dinucleotide; AdoMet, S-adenosylmethionine.

**Tab. S4: Timeline of yTREX application for generation of *P. putida* metabolite production strains**

| Step   | Procedures  | Day    |
|--|---|--------|
| <b>DNA fragment generation</b>                 | PCR or restriction hydrolysis   | 1      |
| <b>Yeast recombinational cloning</b>           | Transformation, incubation, plasmid isolation                                   | 1 - 4  |
| <b>Plasmid amplification in <i>E. coli</i></b> | Transformation, incubation, plasmid isolation, restriction analysis, sequencing | 4 - 7  |
| <b><i>P. putida</i> strain generation</b>      | Conjugational transfer, selection of strains expressing biosynthetic genes      | 7 - 12 |
| <b>Production and analysis</b>                 | Cultivation, extraction, analysis as suitable, e.g. HPLC, spectrophotometry     | 13 - * |

\* Final day depending on the substance and the associated production, extraction and analysis protocols.

## Supplementary References

- [1] Binder D, Bier C, Grünberger A, Drobietz D, Hage-Hülsmann J, Wandrey G, et al. Photocaged arabinose: A novel optogenetic switch for rapid and gradual control of microbial gene expression. *ChemBioChem* 2016;17:296–9. doi:10.1002/cbic.201500609.
- [2] Pridmore RD. New and versatile cloning vectors with kanamycin-resistance marker. *Gene* 1987;56:309–12. doi:10.1016/0378-1119(87)90149-1.
- [3] Loeschke A, Markert A, Wilhelm S, Wirtz A, Rosenau F, Jaeger KE, et al. TREX: A universal tool for the transfer and expression of biosynthetic pathways in bacteria. *ACS Synth Biol* 2013;2:22–33. doi:10.1021/sb3000657.
- [4] Wang H, Stillman DJ. Transcriptional repression in *Saccharomyces cerevisiae* by a SIN3-LexA fusion protein. *Mol Cell Biol* 1993;13:1805–14. doi:10.1128/MCB.13.3.1805.
- [5] Domröse A, Klein AS, Hage-Hülsmann J, Thies S, Svensson V, Classen T, et al. Efficient recombinant production of prodigiosin in *Pseudomonas putida*. *Front Microbiol* 2015;6:1–10. doi:10.3389/fmicb.2015.00972.
- [6] Williamson NR, Fineran PC, Leeper FJ, Salmond GPC. The biosynthesis and regulation of bacterial prodiginines. *Nat Rev Microbiol* 2006;4:887–99. doi:10.1038/nrmicro1531.
- [7] Harris AKP, Williamson NR, Slater H, Cox A, Abbasi S, Foulds I, et al. The *Serratia* gene cluster encoding biosynthesis of the red antibiotic, prodigiosin, shows species- and strain-dependent genome context variation. *Microbiology* 2004;150:3547–60. doi:10.1099/mic.0.27222-0.
- [8] Hoshino T. Violacein and related tryptophan metabolites produced by *Chromobacterium violaceum*: Biosynthetic mechanism and pathway for construction of violacein core. *Appl Microbiol Biotechnol* 2011;91:1463–75. doi:10.1007/s00253-011-3468-z.
- [9] Lee ME, Aswani A, Han AS, Tomlin CJ, Dueber JE. Expression-level optimization of a multi-enzyme pathway in the absence of a high-throughput assay. *Nucleic Acids Res* 2013;41:10668–78. doi:10.1093/nar/gkt809.
- [10] Sánchez C, Braña AF, Méndez C, Salas JA. Reevaluation of the violacein biosynthetic pathway and its relationship to indolocarbazole biosynthesis. *ChemBioChem* 2006;7:1231–40. doi:10.1002/cbic.200600029.
- [11] Guttenberger N, Blankenfeldt W, Breinbauer R. Recent developments in the isolation, biological function, biosynthesis, and synthesis of phenazine natural products. *Bioorganic Med Chem* 2017. doi:10.1016/j.bmc.2017.01.002.
- [12] Mavrodi DV, Bonsall RF, Delaney SM, Soule MJ, Phillips G, Thomashow LS. Functional analysis of genes for biosynthesis of pyocyanin and phenazine-1-carboxamide from *Pseudomonas aeruginosa* PAO1. *J Bacteriol* 2001;183:6454–65. doi:10.1128/JB.183.21.6454.2001.